We'd be surprised if Sera Prognostics, Inc. (NASDAQ:SERA) shareholders haven't noticed that the President, Evguenia Lindgardt, recently sold US$218k worth of stock at US$8.11 per share. That sale was 41% of their holding, so it does make us raise an eyebrow.
See our latest analysis for Sera Prognostics
Sera Prognostics Insider Transactions Over The Last Year
In fact, the recent sale by President Evguenia Lindgardt was not their only sale of Sera Prognostics shares this year. They previously made an even bigger sale of -US$364k worth of shares at a price of US$9.37 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$8.04. So it is hard to draw any strong conclusion from it.
Insiders in Sera Prognostics didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).
Does Sera Prognostics Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data indicates that Sera Prognostics insiders own about US$9.8m worth of shares (which is 3.7% of the company). Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!
So What Does This Data Suggest About Sera Prognostics Insiders?
Insiders haven't bought Sera Prognostics stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. We'd certainly practice some caution before buying! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Sera Prognostics. When we did our research, we found 5 warning signs for Sera Prognostics (1 is a bit unpleasant!) that we believe deserve your full attention.
Of course Sera Prognostics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGM:SERA
Sera Prognostics
A women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States.
Flawless balance sheet medium-low.